Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
RAINFOL-03: Rinatabart sesutecan versus investigator's choice in previously treated endometrial cancer
2024-519818-31-01Phase 3Authorised
- Sponsor
- Genmab
- Start
- Apr 2026
- Modality
- Cytotoxic ADCs → Antibody-Drug Conjugates (ADCs) → Antibody Conjugates → Antibody-Based Therapeutics, Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules
- Countries
- 21
01
Overview
Phase 3, randomised, open-label trial of rinatabart sesutecan in endometrial cancer (EC) (2 arms), sponsored by Genmab. Primary endpoints: Progression-free survival and Overall survival. Planned start Apr 2026; status: authorised.
02
Drugs
rinatabart sesutecan
03
Conditions
endometrial cancer (EC)
Beyond the preview
Go deeper on 2024-519818-31-01.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2024-519818-31-01.